Redeye provides an update following SciBase’s Q2 2026 report.
Redeye updates its estimates and valuation following Collaxio’s Q2 2026 report.
Redeye updates on EG7 after solid Q2-results, driven by Fireshine and the release of Far Far West as...
Redeye updates its estimates and valuation after Boreo’s Q2 2026 report.
* Sales 1% above us, but EBIT 10% below on a softer gross margin * Past the H2'25 trough, larger vol...
The scenario we outlined in our Q2 update has largely materialised, with Xspray reporting a Dasynoc ...
BICO's Q2 report slightly missed on sales as project-based softness persisted, but a sharp margin re...
Redeye views the term sheet and potential for a commercial license agreement with Hipolabor as a log...
Redeye comments on Initiator Pharma’s announcement that the EPO has granted two additional European ...
SynAct Pharma has signed a term sheet with established Brazilian pharmaceutical company Hipolabor fo...
Redeye reads Xplora's Q2 2026 as a volume miss with margins intact.
Redeye provides an initial take following SciBase’s Q2 2026 report.
Redeye comments on Ferroamp’s Q2 report, which showed a strong acceleration in sales and the first q...
Surgical Science delivered a strong Q2, with sales 6% above our expectations and an EBIT margin of 1...
Yesterday, hoenle reported Q3 25/26 results, clearly reflecting turnaround progress despite the guid...
InCoax delivered a better-than-expected Q2, with sales and EBITDA ahead of our estimates, supported ...
Gofore’s Q2 leaves us with increased confidence in organic growth accelerating: the improved signs o...
Despite end-markets remaining mixed and other external headwinds, Alcadon continued on its path of g...
OssDsign managed to stabilise sales in Q2 (flat q/q).
Systemair rapporterar Q1 den 27 augusti med väntad tillväxt på 5 procent och fortsatt stark marginal...
